Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | hydroxyprostaglandin dehydrogenase 15-(NAD) | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Plasmodium falciparum | steroid dehydrogenase, putative | hydroxyprostaglandin dehydrogenase 15-(NAD) | 266 aa | 216 aa | 22.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0232 | 0.8436 | 0.8381 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.0339 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.0339 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0272 | 1 | 1 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0068 | 0.202 | 0.202 |
Loa Loa (eye worm) | TAR-binding protein | 0.0272 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0272 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.0339 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0214 | 0.7718 | 0.7718 |
Echinococcus multilocularis | tar DNA binding protein | 0.0272 | 1 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0232 | 0.8436 | 0.8381 |
Schistosoma mansoni | hypothetical protein | 0.0146 | 0.5081 | 0.3835 |
Schistosoma mansoni | tar DNA-binding protein | 0.0272 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0272 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.0339 | 0.5 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0068 | 0.202 | 0.202 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0068 | 0.202 | 0.174 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0214 | 0.7718 | 0.7718 |
Schistosoma mansoni | tar DNA-binding protein | 0.0272 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0272 | 1 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0232 | 0.8436 | 0.8436 |
Leishmania major | hypothetical protein, conserved | 0.0025 | 0.0339 | 0.5 |
Brugia malayi | hypothetical protein | 0.0025 | 0.0339 | 0.0339 |
Loa Loa (eye worm) | hypothetical protein | 0.0146 | 0.5081 | 0.4908 |
Brugia malayi | TAR-binding protein | 0.0272 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0272 | 1 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0025 | 0.0339 | 0.5 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0214 | 0.7718 | 0.7638 |
Echinococcus granulosus | tar DNA binding protein | 0.0272 | 1 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0146 | 0.5081 | 0.5081 |
Loa Loa (eye worm) | hypothetical protein | 0.0068 | 0.202 | 0.174 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0025 | 0.0339 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0214 | 0.7718 | 0.7638 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0025 | 0.0339 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0272 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7943 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase). (Class of assay: confirmatory) [Related pubchem assays: 2429 (Confirmation qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2407 (Probe Development Summary for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2427 (Thermal Shift Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase))] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS of Nrf2 Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 33.8078 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Inhibitors of Glutaminase (GLS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.